妇科肿瘤化疗患者骨髓抑制危险因素分析  

Retrospective Analysis on Risk Factors of Myelosuppression in Patients with Gynecological Neoplasms and Received Chemotherapy

作　　者：矫洁[1] 周遵伦[1] 黄林[1] 

机构地区：[1]贵阳医学院附院妇科,贵州贵阳550004

出　　处：《贵阳医学院学报》2010年第5期472-475,共4页Journal of Guiyang Medical College

摘　　要：目的:探讨妇科肿瘤患者化疗后骨髓抑制的预防。方法:对272例妇科肿瘤患者化疗前的临床症状、血象及KPS评分等临床资料进行回顾性分析。结果:骨髓抑制发生的相关危险因素有化疗前KPS评分≤60分、多次化疗及化疗前白细胞低于正常;骨髓抑制临床症状多样性,无特异性;在骨髓抑制好发期监测血象及伴随症状,可以预防性治疗,减少骨髓抑制及伴随症的发生。结论:妇科肿瘤化疗患者的骨髓抑制是多种复杂因素共同作用的结果,重视患者化疗前KPS评分、监测骨髓抑制好发期的血象及伴发症状,有助于预防化疗后的骨髓抑制。Objective： To study the method of protecting gynecologic tumor patients against myelosuppression after chemotherapy.Methods： Clinical data including risk factors of myelosuppressio and clinical manifestations of 272 patients with gynecological tumor received chemotherapy were analyzed retrospectively.Results： Risk factors of myelosuppression were KPS scores ≤ 60,multiple chemotherapy,and leukopenia before chemotherapy.The clinical symptoms of myelosuppression were diversity,and non-specific.In the period when myelosuppression was easy to occur,strengthening monitoring on blood and complications,and early detection and treatment,can reduce myelosuppression and incidence of complications,and improve curative results.Conclusions： There are differences among people in terms of risk factors to myelosuppression occurrence.Independent factor can forecast myelosuppression occurrence more accurately,but we can not identify individual factor at present.

关 键 词：卵巢肿瘤 子宫肿瘤 药物疗法 联合 骨髓 

分 类 号：R737.3[医药卫生—肿瘤]